GOSERELIN

The PBAC recommended that the General Benefit listing for goserelin 10.8 mg subcutaneous implant be made unrestricted. The PBAC noted that the submission requested a breast cancer indication be added to the existing PBS listing for goserelin 10.8 mg implant. However, the sponsor had made a further request for an unrestricted listing. The PBAC considered that, among matters, an unrestricted listing for goserelin 10.8 mg would be acceptable at the current AEMP. The PBAC noted and welcomed input from individuals, health professionals and professional organisations. The PBAC acknowledged the importance of having a range of GnRH medicines available on the PBS and supporting patient preferences. The PBAC advised that an unrestricted listing would align with contemporary and evidence-based clinical practice.